 | |
| Clinical data | |
|---|---|
| Other names | Methyldiazirinol; 3,3-Azo-17α-methyl-5α-dihydrotestosterone; 3,3-Azo-17α-methyl-DHT; 3,3-Azo-17α-methyl-5α-androstan-17β-ol; 3-Azi-17α-methyl-5α-androstan-17β-ol |
| Routes of administration | By mouth |
| Drug class | Androgen;Anabolic steroid |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H32N2O |
| Molar mass | 316.489 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methyldiazinol (also known as3,3-azo-17α-methyl-5α-dihydrotestosterone,3-azi-17α-methyl-DHT, or3,3-azo-17α-methyl-5α-androstan-17β-ol) is asynthetic andorally activeandrogen/anabolic steroid (AAS) which was never marketed.[1][2] It is a17α-methylatedderivative ofdihydrotestosterone (DHT); specifically, it is the C3azi (i.e., 3,3-azo)analogue ofmestanolone (17α-methyl-DHT).[1][2] The drug has been found to possess a high ratio and dissociation ofmyotrophic toandrogenic activity; relative tomethyltestosterone, its ratio was 15 (3:0.2), among the highest observed.[1][2]
Methyldiazinol: 3-Azi-17-methyl-5α-androstan-17β-ol: The 3-azi derivative of methandrostanolone was noted by CHURCH et al. (1965) to have a wide myotrophic:androgenic dissociation (3: 0.2) 15 relative to methyltestosterone orally, among the highest noted.
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
